ArticleOncology letters2026
Construction of a novel prediction model based on albumin-hemoglobin score and serum microRNA-497-5p for prognosis of patients with stage II-III colorectal cancer.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stage II-III colorectal cancer (CRC) represents the initial phase of tumor invasion and lymph node metastasis. Surgery is the preferred treatment option for patients at this stage, however, due to the complex progression mechanisms of the disease, incomplete tumor resection, postoperative cancer cell metastasis, and the development of drug resistance to chemotherapy often lead to poor prognosis. The present study aimed to investigate the status of poor postoperative prognosis in patients with stage II-III CRC following radical surgery, analyze the impact of preoperative albumin-hemoglobin (ALB-Hb) score and serum microRNA-497-5p (miR-497-5p) levels on adverse outcomes and develop a predictive model for poor prognosis. Baseline data of 154 patients with stage II-III CRC treated at Tianjin Haihe Hospital (Tianjin, China) or Guangzhou First People's Hospital (Guangzhou, China) between December 2021 and December 2024 were retrospectively selected. Patients were stratified into the poor and good prognosis groups based on clinical outcomes. Univariate analysis was performed on baseline characteristics and laboratory parameters. Variables demonstrating notable differences were subsequently evaluated for multicollinearity. Factors without collinearity were incorporated into a Cox proportional hazards regression model to identify determinants of postoperative prognosis in patients treated with radical resection. These predictors were then used to construct a prognostic nomogram, with model accuracy verified through calibration curves. Among the 154 patients with stage II-III CRC, 63 cases (40.91%) had poor prognosis and 91 cases (59.09%) had good prognosis. Univariate and collinearity analyses revealed marked differences in preoperative levels of miR-497-5p, Kallikrein-related peptidase 5 (KLK5), angiopoietin-2 (Ang-2) and ALB-Hb scores, with no collinearity observed (P<0.05; variation inflation factor ≤10; tolerance ≥0.1). Cox proportional hazards regression model demonstrated that all these indicators were independent factors influencing poor prognosis following radical surgery in patients with stage II-III CRC (all P<0.05). Based on these findings, a nomogram was constructed and calibration curves closely approximated the ideal curve. Preoperative ALB, Hb, miR-497-5p, KLK5, Ang-2 levels and ALB-Hb scores were notable prognostic factors for patients with stage II-III CRC following radical resection, demonstrating high predictive value for poor postoperative outcomes. The present study provided clinically relevant indicators to screen high-risk patients with potential poor prognosis following radical surgery for stages II-III CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.